RecruitingNCT03117036
Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center
Sponsor
Samsung Medical Center
Enrollment
600 participants
Start Date
Mar 1, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Eligibility
Min Age: 20 YearsMax Age: 90 Years
Inclusion Criteria4
- Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- years
- Patients requiring systemic chemotherapy with curative intent
- Written informed consent
Exclusion Criteria3
- Myeloid malignancy
- Multiple myeloma
- Patients do not require systemic chemotherapy with curative intent
Interventions
DRUGChemotherapy
Systemic chemotherapy with curative intent
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03117036
Related Trials
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
NCT02693535166 locations
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT065103613 locations
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
NCT073081327 locations
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT0542166331 locations
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
NCT054425151 location